PROTOCOL

REVIEW ON DESIGNS AND CHALLENGES TO MONITOR CLINICAL BURDEN OF SELECTED MULTIRESISTANT BACTERIA

This report was commissioned by WHO on the 7th July, 2017 under a contract between the WHO and the University of Tübingen, UKET [the contractor], represented and led by Professor Evelina Tacconelli

Reference: WCCPRD5575378

Main output: Review of current research designs and challenges related to the data collection and assessment of the clinical burden of antibiotic resistance as a technical support to prepare future epidemiologic studies with adequate methodologies.

Diletta Pezzani, Evelina Tacconelli, Stephan Harbarth
WHO staff: Camem Pessoa, Barbara Tomimbene
ABBREVIATIONS

AMR: antimicrobial resistance
BSI: bloodstream infection
CAI: community acquired infection
CAZ: ceftazidime
CDI: *C. difficile* infection
CRAB: Carbapenem resistant *Acinetobacter baumannii*
CR-KP: Carbapenem resistant *Klebsiella pneumoniae*
DALY: disability adjusted life years
DRIVE AB: driving re-investment in R&D and responsible antibiotic use
ESBL: extended spectrum β-lactamases
FQ: fluoroquinolone
GBD: global burden of disease
3GC: third generation cephalosporines
GLASS: global antimicrobial resistance surveillance system
GHE: global health estimates
HALE: health life expectancy
HCAI: healthcare associated infection
HQRL: health related quality of life
LOS: length of hospital stay
LRTI: low respiratory tract infection
LTCF: long term care facilities
MDRO: multidrug resistant organisms
MRSA: methicillin resistant *Staphylococcus aureus*
PPL: priority pathogen list
QALY: quality adjusted life years
STD: sexually transmitted disease
UTI: urinary tract infection
VRSA: vancomycin resistant *Staphylococcus aureus*
BACKGROUND

Comprehensive data on the clinical burden of antimicrobial resistance (AMR) are difficult to obtain. Accurate data is vital for convincing governments of the burden that AMR places on the national health and economy and the need of acting rapidly to prevent the situation worsening steadily. Reliable data will be valuable for campaigns to raise public awareness of AMR and for gaining funding for research and surveillance networks. Most current burden data collected on AMR relates to hospital surveillance retrieved from clinical culture and collected mainly in high-income countries. A comprehensive, homogenous and standardized set of epidemiological data is missing. Patient outcomes, direct costs of the additional treatments, antimicrobial use needed as result of AMR and indirect costs linked not only to AMR but also to the impact of quality of life are all key information to set up a proper and methodologic data collection.

WHO’s AMR Surveillance Unit team has already prioritized in its current Global Antimicrobial Resistance Surveillance System (GLASS) work plan to develop protocols for data collection in sentinel sites allowing the generation of variables to be included in AMR burden calculation models, following the approach of the Global Burden of disease (GBD) Study.

The GBD study has grouped the causes of death into three categories, thus defining communicable, maternal, perinatal and nutritional conditions (Group I), non communicable diseases (Group II) and injuries (Group III). Each disease corresponds to specific definitions in terms of the International Classification of Diseases, Tenth Revision (ICD-10). To assess and quantify the impact on global health of disease burden, injuries and risk factors, the GBD has introduced in 1996 a new metric, the disability – adjusted life year (DALY), a summary measure of population health based on estimates of premature mortality and non fatal health loss (Murray 1996). One DALY can be seen as one lost year of healthy life and the measured disease burden is the gap between a population’s health status and that of a normative reference population. The greater the time lived with a disability, or with the disabling results of illness or the most time lost due to premature death, the greater the burden of the disease is considered to be. DALYs for a specific cause are calculated as the sum of Years Lived with Disability (YLD) and Years of Life Lost due to premature mortality (YLL).

\[
\text{DALY} = \text{YLD} + \text{YLL}
\]

\[
\text{YLD} = I \times \text{DW} \times \text{L}
\]

\[
\text{YLL} = N \times \text{L}
\]

Another population health summary measure is the Quality Adjusted Life Year (QALY), generally used to analyse the cost – effectiveness of clinical (or public health) interventions and for social welfare
improvement. QALYs are calculated by multiplying the number of years of additional life by a Health related Quality of Life (HQRL) value. HRQL is based on values assigned by individuals about their own state or on values assigned by others about a particular health state.

The last GBD 2015 results for DALYs and Healthy Life Expectancy (HALE) 1990-2015 found a reduction in DALYs from Group I diseases with significant declines of total burden, among infectious diseases, of lower respiratory tract infections (LRTI), diarrhoeal disease, tuberculosis, meningitis, malaria, tetanus, measles and HIV/AIDS (Kassebaum, 2016). Despite the inclusion in the global health estimates (GHE) cause categories of almost all main causative agents of infectious diseases (comprehensive of the GLASS target bacteria) and the continuous inclusion of new ones (such as acute hepatitis A and E, cysticercosis, echinococcosis, yellow fever, food-borne trematodosis), categories like health care associated infections (HCAI) and antimicrobial resistant bacteria are not considered yet. Given that these latter two represent emerging and growing health threats, it has been suggested that they should be analyzed by the GBD like estimates for multidrug resistant tuberculosis, which is already planned for the future rounds of the GBD (Kassebaum 2016; Vos 2016).

Major obstacles to the calculation of DALYs for antimicrobial resistance are represented by the lack of incidence and epidemiological data gathered through standard and uniform reports around the globe and comprehensive, methodologically sound data on clinical burden of AMR.

**AIM OF REVIEW**

To perform a comprehensive review of current research designs and challenges related to the adequate data collection and assessment of the clinical AMR burden. The data will contribute to the better understanding of the potential impact of selected antibiotic resistant bacteria and prepare future epidemiologic studies with adequate methodologies, within the GLASS framework.

**METHODS**

**Design:** review of literature (no limit – Sept 2016)

**Inclusion criteria:**

- Published studies on human subjects focusing on the GLASS target bacteria (see table 1) and the following clinical syndromes (included in the GBD) categorized according to the ICD-10 codes (2016 version):
  
  I. **Bloodstream infections (BSI):** sepsis due to *Streptococcus pneumoniae* (A40.3), sepsis due to *Staphylococcus aureus* (A41.0), sepsis due to other Gram negative organisms (A41.5), systemic inflammatory response syndrome of infectious origin with or without organ failure (R65.0., R65.1)
  
  II. **Meningitis:** bacterial meningitis (G00)
  
  III. **Lower respiratory tract infections (LRTI):** pneumonia due to *Streptococcus pneumoniae* (J13), bacterial pneumonia (J15).
  
  IV. **Urinary tract infections (UTI):** urinary tract infection (N39).
  
  V. **Intestinal infectious diseases:** diarrhoeal diseases such as typhoid and paratyphoid fevers (A01), other Salmonella infections (A02), Shigellosis (A03), other bacterial intestinal infections (A04.0-A04.4).
  
  VI. **Sexually transmitted disease:** gonococcal infection (A54)
- Reporting at least one clinical outcome measures and / or
- Reporting QALY or DALY as indirect outcome.

**Exclusion criteria**
- Diagnostic and microbiological studies, reviews and non-clinical studies
- Study protocols
- Studies exclusively focusing on risk factor for acquisition of infections due to antibiotic resistant bacteria (however, risk factors studies providing at least one clinical outcome measure of interest will be included)

**Types of studies**
- All study design
- Conducted in hospital, community and other healthcare center (including long term care facilities and nursing homes)
- All population with no age limit

**Target bacteria**
All bacteria included in the GLASS study will be considered for this review.

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Resistance type</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Escherichia coli</em></td>
<td>Fluoroquinolones (FQ), third generation cephalosporines (3GC), carbapenems</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
<td>3GC, Carbapenems</td>
</tr>
<tr>
<td><em>Acinetobacter baumannii</em></td>
<td>Carbapenems</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Methicillin, vancomycin</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>Penicillin non susceptible</td>
</tr>
<tr>
<td><em>Salmonella</em> spp</td>
<td>FQ</td>
</tr>
<tr>
<td><em>Shigella</em> spp</td>
<td>FQ</td>
</tr>
<tr>
<td><em>Neisseria gonorrhoeae</em></td>
<td>FQ, 3GC</td>
</tr>
</tbody>
</table>

**Sources of data and search strategies**

**Existing databases** (databases from two running projects at UKET)
- **DRIVE-AB project.** A multinational project aiming to gather data from worldwide surveillance systems, antibiotic prescription databases and published literature in order to estimate the present and the future burden of antibiotic resistance from both clinical and economic perspectives. The research results will feed into the development and testing of new alternative economic models to incentivize investment in antibacterial drug research and development. The UKET database contains results from a systematic review and meta-analysis on all published studies analyzing the mortality
and length of stay (LOS) in patients with infections due to the following resistant bacteria: *carbapenem-resistant and carbapenemase producing Enterobacteriaceae (including Klebsiella, E. coli and Proteus spp.), Pseudomonas spp. and Acinetobacter spp.* compared with patients with sensitive infections or randomly chosen.

**Inclusion criteria:** published studies on human subjects studying multidrug resistant organism (MDRO) of interest and reporting at least one of the outcome measures with presence of a comparison group or a subgroup comparison. Studies evaluating colonisation, study protocols, diagnostic studies, reviews, non-clinical studies were excluded.

**Data sources:** MEDLINE, 1950-up to September 2016, In-Process and other non-indexed citations, OvidS.

- **WHO Pathogen Priority List (PPL) study.** The major goal of the WHO priority list is to prioritize funding and facilitate global coordination of strategies for the discovery of new antibiotics to treat acute bacterial infections. The UKET database includes the outcomes data for all the DRIVE-AB bacteria plus fluoroquinolones (FQ)-resistant *Campylobacter spp*, ampicillin-resistant *Haemophilus influenza*, clarithromycin-resistant *Helicobacter pylori*, 3GC and FQ -resistant *Neisseria gonorrhoeae*, FQ-resistant non-Typhoidal *Salmonella* and *S. typhi*, FQ-resistant *Shigella spp* and penicillin-non-susceptible *Streptococcus pneumoniae*.

  **Inclusion criteria:** published studies on human subjects reporting data on mortality/LOS/ and antibiotic resistant bacteria and including a comparison group (either patients with infections due to sensitive bacteria or randomised patients without infections); published studies on human subjects reporting data on recurrence of infections due to resistant bacteria within one year of the first episode.

  **Data sources:** MEDLINE, 1950-up to September 2016, In-Process and other non-indexed citations, OvidS.

**Search terms included in the DRIVE AB and WHO PPL projects:**


Each term was then coupled with the search term built for the specific bacteria

Search term from the WHO-PPL:

- microbiology"[MeSH Terms] OR "microbiology"[All Fields] OR "microbiological"[All Fields] AND failure[All Fields] OR ("recurrence"[MeSH Terms] OR "recurrence"[All Fields]) AND ("recurrence"[MeSH Terms] OR "recurrence"[All Fields] OR "relapse"[All Fields]) and target resistant bacteria


- Shigella: shigella[Mesh] OR shigella[tw]

Data extraction

All articles included in the DRIVE-AB and the WHO-PPL will be reanalyzed for the relevant variables (quality control of extracted data). Reasons from exclusion from the previous databases will be analyzed to check for possible inclusion in the current research project (other outcomes as mortality and LOS).

Table 2 summarizes the list of variables extracted and included in the existing databases:

<table>
<thead>
<tr>
<th>Study related variables</th>
<th>Study population</th>
<th>Study design</th>
<th>MDRO</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
<td>Population profile</td>
<td>Type of the study</td>
<td>Bacteria</td>
<td>Mortality (definition)</td>
</tr>
<tr>
<td>Institute</td>
<td>Setting</td>
<td>Aim of the study</td>
<td>Type of resistance</td>
<td>LOS (definition)</td>
</tr>
<tr>
<td>Country</td>
<td>Clinical syndrome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year of publication</td>
<td>Tot no. recruited</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title of the article</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Journal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time of data collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2

Outcomes

All outcomes analyzed in the studies will be reported, including but not limited to the following:

- Mortality: all cause mortality, attributable mortality, 30 day mortality, long-term mortality
- Complications: need for surgery/ Intensive care unit (ICU) admission/ super-infection/ Clostridium difficile infection (CDI) / need for rehabilitation, admission to LTCFs
- Length of stay (in hospital/ ICU/post-infection)
- Duration of disease
- Hospital readmission
- Days of school lost, absenteeism from work
- QALY and DALY (for the assessment of indirect outcome of disease burden).

The following new variables on the study design will also be added:

- Research question
- Demographics (age, sex)
- Duration of the study
- Description on how and when outcomes were measured (including evidence that the tests/instruments used to measure are valid)
- Statistical methods used to compare outcomes (including descriptive statistics on the study sample; control group selection)
- Controlling for confounding (adjustment for LOS, comorbidities, time of antibiotic exposure and effectiveness; multiple population)
- Methods to assess QALY and DALY
- Follow-up time
A second search will be performed to evaluate the studies analyzing the impact of infections due to antibiotic resistant bacteria on the quality of life. Since we expect not to find enough evidence for resistant strains, the search will be extended to severe bacterial infections due to the target bacteria (regardless the susceptibility pattern).

**Search terms:**
- (school* OR work) AND (absen* OR day)

**Quality assessment**
Modified EPOC assessment criteria for RCTs, NewCastle Ottawa quality assessment scale for case control studies and cohort studies will be used.

**RCTs**
- Generation of allocation sequence adequate? (Yes/No/Unclear)
- Allocation concealment adequate? (Yes/No/Unclear)
- Validated and reliable primary outcome measures/systems are used? (Yes/No/Unclear)
- Baseline/primary outcome measurements similar? (Yes/No/Unclear)
- Baseline/primary characteristics similar? (Yes/No/Unclear)
- Adequate addressing of incomplete data outcome? (Yes/No/Unclear)
- Blinding to primary outcome achieved? (Yes/No/Unclear)
- Adequate protection against contamination? (Yes/No/Unclear)

**Case Control**
- Is the case definition adequate? (yes, no, unclear)
- Representativeness of the cases (consecutive or obviously representative series of cases, potential for selection biases or not stated)
- Selection of Controls (community controls, hospital controls ,no description)
- Definition of Controls (no history of disease (endpoint), no description of source)
- study controls for the most important factor (yes, no, unclear)
- study controls for any additional factor (yes, no, unclear)
- Ascertainment of exposure (secure record (eg surgical records), structured interview where blind to case/control status, interview not blinded to case/control status, written self report or medical record only, no description)
- Same method of ascertainment for cases and controls (Yes/No/Unclear)
- Non-Response rate (same rate, non respondents described, rate different and no designation)

**Cohort studies**
- Representativeness of the exposed cohort (truly representative, somewhat representative , selected group of users, no description)
- Selection of the non exposed cohort (drawn from the same community as the exposed cohort, drawn from a different source, no description of the derivation of the non exposed cohoh
• Ascertainment of exposure (secure record (eg surgical records), structured interview, written self report, no description)
• Demonstration that outcome of interest was not present at start of study (Yes/No/Unclear)
• Comparability of cohorts on the basis of the design or analysis (study controls for the most important factor, study controls for any additional factor)
• Assessment of outcome (independent blind assessment, record linkage, self report, no description)
• Follow-up long enough for outcomes to occur (Yes/No/Unclear)
• Adequacy of follow up of cohorts (complete follow up – all that matters subjects accounted for, subjects lost to follow up unlikely to introduce bias - small number, inadequate numbers but description provided of those lost, inadequate follow up rate and no description of those lost, no statement.

Estimated workload

• Abstracts to be reviewed based on previous searches: 2226
• Papers to be included: around 500 (23%)

<table>
<thead>
<tr>
<th></th>
<th>DRIVE AB search</th>
<th>WHO PPL search</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbapenem resistant Acinetobacter baumanii and Klebsiella pneumoniae</td>
<td>70</td>
<td>-</td>
</tr>
<tr>
<td>ESBL and FQ resistant Enterobacteriaceae</td>
<td>800</td>
<td>-</td>
</tr>
<tr>
<td>MRSA and VRSA</td>
<td>152</td>
<td>-</td>
</tr>
<tr>
<td>Jan-Sept 2016 update (includes ESBL, carbapenem resistant Enterobacteriaceae, MRSA and VRSA)</td>
<td>198</td>
<td>-</td>
</tr>
<tr>
<td>Salmonella spp</td>
<td>-</td>
<td>197</td>
</tr>
<tr>
<td>Shigella</td>
<td>-</td>
<td>46</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>-</td>
<td>777</td>
</tr>
<tr>
<td>Neisseria gonorrhoeae</td>
<td>-</td>
<td>26</td>
</tr>
<tr>
<td>TOTAL</td>
<td>1220</td>
<td>1046</td>
</tr>
</tbody>
</table>

Bibliography

